Teal is the awareness color of ovarian cancer. Women of Teal is a play on the words "Man of Steel" used to describe Superman. I have found my fellow ovarian cancer survivors to be the strongest, most helpful women in the world. They are truly Women of Teal!
I watched this gyn cancer Education Session a day later. I appreciate that ASCO provides participants access to the videos after the session has run.
Homologous Recombination Proficient disease
Watched on demand 6/5 Challenges in OC #ASCO22#gyncsm@SwisherLiz Maintenance options with HR proficient Disease (HRP mechanism by which DNA damage can be corrected) HRP is not a driver event. Some benefit and high cost of PARP use in those without HR deficiency, pic.twitter.com/8wszbexlzh
Repeating PARP maintenance in ovarian cancer recurrence may have only a small benefit.
Watched on demand 6/5 #ASCO22#gyncsm Challenges in OC @CoquardRay Recurrent Maintenance Options in Patients With Prior Maintenance Therapy PARP use in maintenance has improved PFS. Repeat PARP benefit is small Evidence supports use of Bev pic.twitter.com/bjzSCIOzsl
Watched on demand 6/5 #ASCO22#gyncsm Challenges in OC @CoquardRay presents good ?'s for patients and survivors: Should Endpoints be weighted for PRO and QOL? What are patient expectations? pic.twitter.com/OTAm2VDpCx
6/5 Challenges in OC #ASCO22#gyncsm Van Driel - HIPEC: Is It Ready for Prime Time in Ovarian Cancer? Multidisciplinary team and surgical skills needed to use HIPEC.
Below find some interesting ovarian cancer research studies I heard at the SGO meeting.
Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress
Long Term Survival of GOG 252 'Randomized Trial of Intravenous Versus
Intraperitoneal Chemotherapy plus Bevacizumab in Advanced Ovarian
Carcinoma: An NRG Oncology/GOG Study' J. Walker
#SGOmtg. Dr Walker GOG 252 - no gross residual disease population - Can you completely resect? Can you get CA125 to less than 10 in 3 cycles. #gyncsmpic.twitter.com/qMksxlPgFx
What's Next After Bevaciumab Resistance? Targeting Metabolic Vulnerabilities in Ovarian Cancer – D. Glassman GLSi is a novel therapeutic strategy to treat AVA-resistant ovarian cancer
Final Overall Survival Results from SOLO3: Phase III Trial Assessing
Olaparib Monotherapy Versus Non-Platinum Chemotherapy in Heavily
Pretreated Patients with Germline BRCA1 and/or BRCA2-Mutated
Platinum-Sensitive Relapsed Ovarian Cancer – R. Penson
Investigation of PARP Inhibitor Resistance Through the Analysis of
Serially Collected Circulating Tumor DNA (ctDNA) in Ovarian Cancer
Patients – Speaker: Y. Kim
Evolution of the Ovarian Cancer Treatment Paradigm, Including
Maintenance Treatment, in the US and Europe: A Real-World Chart Review
Analysis (2017-2020) – Speaker: K. Moore
Knowledge Measure for Ovarian Cancer Research (KnoMOR): Development and
Psychometric Testing Results of a Patient-Centered Knowledge Measure –
Speaker: L. Meyer
Yes!! Dr. Larissa Meyer: Knowledge is a prerequisite to informed choice. Development of KnoMOR (Knowledge Measurement for Ovarian Cancer Research) Shared decision making tool. #SGOmtg#GYNcsmpic.twitter.com/miuAi5ZGuD
Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress
OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian
Cancer Following Front-Line Platinum-Based Chemotherapy with
Bevacizumab: Updated Analysis – Speaker: M. Hardesty
Prospective, Randomized Trial of Streamlined Genetic Education and
Testing for Patients with High Grade Epithelial Ovarian, Fallopian and
Peritoneal Cancer – Speaker: R. Previs
Effectiveness of Platinum-Based Chemotherapy after Progression on Poly
ADP Ribose Polymerase (PARP) Inhibitor in Epithelial Ovarian Cancer –
Speaker: K. Dugan
Scientific Plenary III: Novel Therapeutics: The Expanding Toolbox
A Novel Combo of Niraparib and Anlotinib in Platinum-Resistant Ovarian
Cancer, the Final Efficacy and Safety Report of ANNIE Study, a Phase II,
Multi-Center Trial – Speaker: J. Liu , This is a Niraparib and Anlotinib ( kinase inhibitor) combo used in Platinum-Resistant OC (ANNIE Study)
Promising combo With tolerable toxicity . PPMD1 mutation may be what leads to resistance in niraparib.
Updated Results from the Phase 1 Expansion Study of Upifitamab
Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug
Conjugate (ADC) in Ovarian Cancer – D. Richardson
#SGOmtg Ph1 Expansion Study of Upifitamab Rilsodotin (UpRi NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer - Dr Richardson , 97 patients in 2 groups , no severe toxicity, prior lines ORR 44% in NaPi 2b expression patients #gyncsmpic.twitter.com/c8a3Idtj0A
Clinical Outcomes of Ovarian Cancer Patients Treated with the Novel
Engineered Cytokine Nemvaleukin Alfa in Combination with the PD-1
Inhibitor Pembrolizumab: Recent Data from ARTISTRY-1 – Speaker: I. Winer
#SGOmtg Ovarian Cancer Treated with the Novel Engineered Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab ARTISTRY-1 – Dr I. Winer 16 patients treated, 5 had response. Well tolerated. Evidence of tumor response , FDA fast track Designation #gyncsmpic.twitter.com/9tyvTZFOvK
#SGOmtg Dr Matulonis Soraya study : High folate expressing ovarian cancer treated with mirvetuximab MIRV antibody drug conjugate ORR 34%, mDOR 6.9 months 5 complete responses mPFS 5.4 mo AE ocular events( blurred vision) were reversible , nausea #gyncsmpic.twitter.com/oNV8XjpoEG
#SGOmtg PRIME study - niraparib as maintenance in newly dx adv OC individual dosing PFS 24.8 months with Niraparib vs 8.3 months in placebo Immature OS . #gyncsmpic.twitter.com/kbAz1QBJzk
#SGOmtg Dr Gershenson presenting on LGSOC using NGS Characteristics : Young age, relative chem resistance, responds to endocrine therapy #gyncsmpic.twitter.com/QzYZfJ7SGw
Scientific Plenary V: Bullseye! Precision Medicine and Hitting the Right Targets
RNAseq Correlative Biomarkers IFIT1B and VSTM5 Predict Progression Free
Survival and Clinical Benefit in a Multi-Site Phase I/II Trial of
Olaparib and Tremelimumab for gBRCAm Recurrent Ovarian Cancer –
S. Adams
#SGOMtg Dr Adams Olaparib and Tremelimumab ( CTLA4 In women with OC with BRCA mutations Combo may be a benefit for a subset of women with OC #gyncsmpic.twitter.com/7rwhexJQ02
#SGOMtg Dr Adams Olaparib and Tremelimumab ( CTLA4 In women with OC with BRCA mutations Combo may be a benefit for a subset of women with OC #gyncsmpic.twitter.com/7rwhexJQ02
Turning Cold into Hot: Combination of Pembrolizumab with Bevacizumab and
Oral Metronomic Cyclophosphamide Increases Immune Cell Migration into
the Tumor Microenvironment in Responding Patients with Recurrent Ovarian
Cancer – N. Gaulin
The Role of Mesenchymal Stem Cells in the Ovarian Cancer Precarcinoma Microenvironment – Speaker: T. Orellana
Defining the Impact of Chromobox 2 on the Immune Tumor Microenvironment
of High Grade Serous Ovarian Carcinoma – L. Brubaker
#SGOMtg Dr Brubaker CBX2 ( epigenetic transcription regulator has high expression in HGSOC , poor survival. Mouse study - less tumor when CBX2 knocked down . CBX2 directly regulates micrenvironment Working on CBX2 inhibitor . #gyncsmpic.twitter.com/vOkLKxauYx
Here are highlights from the Virtual #SGOmtg sessions I attended on Saturday March 20, 2021.
The morning began with a wonderful get-together for Patient Advocates at a 9am session. I am so glad to see patient advocates play a role in so many aspects of the SGO organization.
In real time, I shared information on Twitter( @womenofteal) about the
sessions I attended using the #gyncsm and #SGOmtg hashtags
Surgery:
Scientific Plenary II: Cutting Edge - Advancing Surgical Innovation -If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer Dr Katelyn Handley- Looking at morphology and molecular difference in OC #SGOMtg#gyncsm#SGOPatAdvpic.twitter.com/LavQt2RBLp
Higher Surgical Volume is Associated with Better Outcomes for Frail Patients Undergoing Surgery for Ovarian Cancer- M. Nakhla #SGOMtg#gyncsmpic.twitter.com/3ZU7q8KZ0R
Education Forum V: Eradicating Racism and Discrimination in Medicine Thank you Dr Latimore. #SGOMtg#gyncsm Have you ever taken a test to measure your implicit bias? I have. Results were not what I expected. We can do better. "See people as an individual." pic.twitter.com/bCEYQ1IDiY
Education Forum V: Eradicating Racism and Discrimination in Medicine #SGOMtg#gyncsm Dr Marsh "We have to see it." "Honesty is more important than fear" We need to do this now. pic.twitter.com/48BS8u4I2B
— Payam Katebi Kashi, MD, PhD (@PayamKashiMD) March 20, 2021
PAOLA-1 Olaparib plus Bev
Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials HR repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial E. Pujade-Lauraine#SGOMtg#gyncsmpic.twitter.com/sEUkrDBAzJ
Updated data from the KEYNOTE-158 study of pembrolizumab in recurrent #cervicalcancer - response rate of 17% in pts with PD-L1 positive tumors. Median time to response was 2 months- fast acting! Med duration of response not reached... #SGOMtg#gyncsmpic.twitter.com/ut0EinNBvy
Scientific Plenary III: Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study H. Chung#SGOmtg#gyncsmpic.twitter.com/qdBegPgXfZ
Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials Dr Matulonis ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian #SGOmtg#gyncsmpic.twitter.com/wwd9DwuTho
Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials Bradley Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials Longest duration of follow -up of a PARP inhibitor in trials to date. #SGOmtg#gyncsmpic.twitter.com/hFNBwgsZ5K
#SGOmtg Translational Research 2021: Genomic profiling of adv cervical cancer to predict response to PD-1 inhibitor combination therapy: a secondary analysis of the CLAP trial #gyncsm C. Lan predictive Biomarker research for cervical cancer pic.twitter.com/IuoDprILOi
Phase III Ran Trial of Postoperative Adjuvant Conventional Radiation (3DCRT) vs Image Guided Intensity Modulated Radiotherapy (IG-IMRT) in Cervical Cancer (PARCER) S. Chopra Reduction in diarrhea, #sgomtg#gyncsmpic.twitter.com/iGgp0EEcdF
Priority Assessment for Women with Recurrent Ovarian Cancer: A Pilot Study presented by @StephanieVBlank Aids shared-decision making! Feasible with 97% completion! Next steps: Ongoing assessments, electronic version, languages #SGOmtg#SGOPatAdv#GYNcsmpic.twitter.com/hF4ntyzCwk
I was happy to be able to attend the virtual SGO Annual Meeting. The meeting started on Friday, March 19 with sessions during the day and evenings over the weekend. The meeting continues with evening sessions through Thursday March 25th. Interacting with presenters and others in the chat feature of the meeting platform was exceptionally good and helpful.
In real time, I shared information on Twitter( @womenofteal) about the sessions I attended using the #gyncsm and #SGOmtg hashtags. Below are some tweets of Fridays sessions I found most interesting.
Friday
Nutritional Supplements
Now Watching: Catching Up to Speed on the Role of Nutritional Supplements in the Management of Gynecologic Cancer Patients w/ Dr Smith #SGOMtg#SGOPatAdv#GYNcsm Patient use of supplement has increased up to 60%. Wealth of info like below. pic.twitter.com/OM17J62Q01
Patients: Please talk to your medical team ASAP if you are currently on treatment & taking any of these supplements! #SGOmtg session: Catching Up to Speed on the Role of Nutritional Supplements in the Management of Gynecologic Cancer Patients w/J Smith PharmD #SGOPatAdv#GYNcsmpic.twitter.com/fHW2HP8BtV
#sgomtg Navigating High Stakes Conversations in Gynecologic Oncology great discussion on those difficult discussions using VITALtalk Excellent consideration of patient goals and needs. #gyncsmpic.twitter.com/GHfNnXrXkR
Listening to PARP Inhibitors: A Practical Approach to Selection and Management : Karen Lyle, PA-C , Colleen McCormick, MD, MPH Excellent overview of trial results of PARP use and its current approval for use. #SgoMtg#gyncsmpic.twitter.com/Ph1IOS13Js
Dr. Arend presents exciting data of a DKK1 inhibitor (DKN-01) in #endometrialcancer - biomarker selection seems possible using DKK1 expression, WNT mutation or PIK3CA mutation. Will be exciting to see this move forward! #SGOMtg#gyncsmpic.twitter.com/nz9yDpKyNp
Viewing an On-Demand session-Diversity and Inclusion: Impact of Historical Bias in Gynecologic Oncology #SGOMtg Dr Jeffrey Hines #gyncsmpic.twitter.com/xEnumzoUTB
It was my pleasure and an honor to be named one of ASCO's Featured Voices for this year's annual meeting.
Over the course of the next few days I will be highlighting the research studies presented at the #ASCO20 Virtual Annual Meeting. I will share posters, oral abstracts and presentations on gynecologic oncology, survivorship, cancer disparities and the impact of COVID 19 on cancer patients . I will also share parts of ASCO President Skip Buris's address and the keynote address by author, physician and cancer survivor Dr David Fajgenbaum.
Since my Voice was active on Twitter I will share the tweets I wrote as well as ones I retweeted.
Today, I will begin with gynecologic cancer studies.
Surgery on Recurrence - Ovarian Cancer Abstract 6000
Final analysis of AGO DESKTOP III/ENGOT-ov 20#6000 Secondary cytoreductive surgery(SRC) in recurrent ovarian cancer (ROC) Dr DuBois
“OS benefit >12 mos for pts with complete resection (CR) compared to pts without surgery (median 60.7 vs. 46.2 mos) #gyncsm#ASCO20#OVCA 1/2
Secondary CRS in ROC is back to the game, good selection of your patients & high quality surgery will significantly improve survival #gyncsm... Choose them wisely & aim for complete CRS... pic.twitter.com/148HpeCGml
#6001 phase III trial of secondary cytoreductive surgery (CSR) in later recurrent ovarian cancer: SOC1/SGOG-OV2
Select Patients(predicted R0 surgery)extension of PFS to start of first subsequent therapy (TFST) 1/2 pic.twitter.com/6Y4hFmO9g5
PFS was 18.1 m vs 13.6 m in favor of the surgery arm #gyncsm#ASCO20#OVCA Dr R Zang
If you want to learn more head over to this YouTube video ( https://youtu.be/22UFGOGZ9lI ) featuring Dr Coleman's ASCO “Dissecting Out Improved Outcomes.” via #SGOatASCO.
PARP Inhibitors - Ovarian Cancer Abstract 6002
#6002 Final overall survival (OS) results from SOLO2/ENGOT-ov21
Maintenance olaparib provided an improvement of 12.9 months in median OS vs placebo. #gyncsm#ASCO20#OVCA Dr A Poveda pic.twitter.com/OYyEkPXy6E
Olaparib w/ Cediranib - Ovarian Cancer Abstract 6003
#6003 phase III comparing olaparib or combo cediranib and olaparib to std plat chemo in recurrent plat-sensitive #ovca Dr Lui "C+O demonstrated similar activity to SOC in relapsed plat-sensitive ovca but did not meet the primary endpoint of improved PFS" 1/2 #gyncsm#ASCO20
This was an all oral non-platinum treatment trial. Cediranib is a tyrosine kinase inhibitor for VEGFR1,2,3. Protocol was amended to allow maintenance therapy.
Folate receptor - Ovarian Cancer Abstract 6004
Ab 6004 Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), combo w/ bev in patients (pts) w/ platinum-agnostic ovarian cancer.
overall response rate (ORR) of 43%, high FRα expressing tumors ORR was 61% #gyncsm#ASCO20#OVCA
Ovarian Cancer exhibits a folate receptor alpha (FRα).
Adverse Events included diarrhea , blurred vision , nausea , and fatigue.
Dr Gilbert presented.
Pembolizumab PD-1 - Ovarian Cancer Abstract 6005
6005 KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. Pembro monotherapy Increased ORR & trend to higher OS with >PD-1 expression Median OS was 18.7 months overall, Dr Matolunis https://t.co/2eRjkNFc5K#gyncsm#ASCO20#OVCA
If you can learn more about these studies by watching this video of Dr. Banerjee’s presentation, “Stay Sharp on PARP and More.” #SGOatASCOhttps://youtu.be/ZTUyn8vPZ2Q
Olaparib LIGHT Study - Ovarian Cancer
Abstract 6013
Poster 6013:Olaparib in pts with platinum-sensitive relapsed (PSR) #ovca by BRCA mutation (BRCAm) & homologous recombination deficiency (HRD) status: LIGHT study.
Similar Olaparib efficacy was seen in the gBRCAm and sBRCAm cohorts #gyncsm#ASCO20 1/2
Despite
guidelines dating back to 2008 that all ovarian cancer patients should
have BRCA1/2 testing (either germline or somatic), #cancerlinq RWE shows that only 22.6% of ovarian patients actually received testing. Huge opportunity for incr. education. #ASCO20#gyncsmpic.twitter.com/dn0U8B0BQz
— Jamie Holloway, PhD (@jamienholloway) May 29, 2020
Niraparib and bevacizumab Ovarian Cancer Abstract 6012
# 6012 Poster Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive #ovca —A randomized controlled chemotherapy-free study.#gyncsm#ASCO20#OVCA
PFS demonstrates that the niraparib-bevacizumab combination had clinically and statistically meaningful results. Trial not powered for other endpoints Dr Mirza #gyncsm#ASCO20#OVCApic.twitter.com/xRCwkH9PLz
Interesting I/O poster by Klein et al. Abstr #302065
Volunteers: All with rare gyn cancers (n=43)
Intervention: Ipi+Nivo
Comparator: NA
Outcome: ORR 28%
*Clear cell cancer (n=6): ORR 33% (1 CR seen)#gyncsm#ASCO20
STARS study of adjuvant RT v sequential (SCRT) v concurrent (CCRT) chemoRT in IB1-IIA2 cervical ca #ASCO2020#gyncsm#OncoAlert
1° endpoint: DFS
👉⬆️LN+ SCRT/CCRT,⬆️compliance RT alone
👉SCRT⬆️DFS, DRFS, even vCCRT! Most in HR subgroup
👉SCRT⬆️OS vRT alone
👉❌diff long-term QoL pic.twitter.com/yKC5joE1Sh
— Nat Lester-Coll, MD (@DrLesterColl) May 29, 2020
For recurrence, the main advantage for sequential chemoRT was in reducing the risk of distant recurrence. 4-year local recurrence rates <10% for intermediate risk, 10-15% for high risk in all arms.
Gr3 toxicity in sequential CRT arm< concurrent CRT #ASCO20#gyncsm
G5/
Over the past few weeks many questions about PARP inhibitor use in the treatment ( front line, recurrent and maintenance) therapies for Ovarian Cancer were asked in many of the private online groups that I participate in. I can understand the questions and confusion because of the different PARPs available for women diagnosed with ovarian cancer - Olaparib ( Lynparza) , Niraparib ( Zejula) and Rucaparib (Rubraca) and their uses.
In this blog post I will describe what a PARP inhibitor is, and provide all the FDA approval information and a few articles that compare the different types.
Let's start with this definition provided by the NCI.
PARP inhibitor
"A substance that blocks an enzyme in cells called PARP. PARP helps
repair DNA when it becomes damaged. DNA damage may be caused by many
things, including exposure to UV light, radiation, certain anticancer
drugs, or other substances in the environment. In cancer treatment,
blocking PARP may help keep cancer cells from repairing their damaged
DNA, causing them to die. PARP inhibitors are a type of targeted
therapy. Also called poly (ADP-ribose) polymerase inhibitor."
I'm more a visual person so here is a video by Dana Farber that you might find helpful.
Now lets look at each PARP and when , who and why it was approved. The FDA pages include references to the clinical trials that the approval was based on. Remember there are still clinical trials enrolling that may use a PARP in combination with other treatments.
Olaparib:Lynparza
2014 FDA Approval Summary: Olaparib Monotherapy in Patients with
Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with
Three or More Lines of Chemotherapy. https://www.ncbi.nlm.nih.gov/pubmed/26187614
2017
On Aug. 17, 2017, the U.S. Food and Drug Administration granted regular
approval to olaparib tablets (Lynparza, AstraZeneca) for the maintenance
treatment of adult patients with recurrent epithelial ovarian,
fallopian tube, or primary peritoneal cancer, who are in a complete or
partial response to platinum-based chemotherapy.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer
2017
On March 27, 2017 , the U.S. Food and Drug Administration approved
niraparib (ZEJULA, Tesaro, Inc.), a poly ADP-ribose polymerase (PARP)
inhibitor, for the maintenance treatment of adult patients with
recurrent epithelial ovarian, fallopian tube, or primary peritoneal
cancer who are in complete or partial response to platinum-based
chemotherapy. https://www.fda.gov/drugs/resources-information-approved-drugs/niraparib-zejula
2019
On October 23, 2019,the Food and Drug Administration approved niraparib
(ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian
tube, or primary peritoneal cancer treated with three or more prior
chemotherapy regimens and whose cancer is associated with homologous
recombination deficiency (HRD)-positive status. HRD is defined by either
a deleterious or suspected deleterious BRCA mutation, or
genomic instability in patients with disease progression greater than
six months after response to the last platinum-based chemotherapy. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer
Rucaparib: Rubraca
2016
On December 19, 2016, the U.S. Food and Drug Administration granted
accelerated approval to rucaparib (RUBRACA, Clovis Oncology Inc.) for
treatment of patients with deleterious BRCA mutation (germline and/or
somatic) associated advanced ovarian cancer who have been treated with
two or more chemotherapies.
Here is a short summary( Tweets) and notes from the Gyn Cancer Education Sessions I attended at this year's ASCO Annual Meeting. Please note these sessions were not necessarily only ovarian cancer sessions.
Abstracts are available online at https://abstracts.asco.org/239/IndexView_239.html
6/1/2019 Pharma to Table
Levinson - Immunotherapy in Gyn Cancers
Rubin- Recognizing and Managing Immun-related Toxicities
irAE = immun-related Adverse Events
Events could include - cough, colitis, endocrine issues, pneumonitis
With adverse events is was recommended to not reduce the dose but rather hold the dose
Dorigo - The Future of Immunotherapy in Gyn Cancers
TIL - Tumor Infiltrating Lymphocytes
Trials ongoing with HPV positive ovarian cancer ( yes , HPV can cause more than cervical and head and neck cancers. ) , CAR-T cells and vaccines
Trials like this one opening soon.
6/2/2019 Are We Hitting the Bull's -eye with Targeted Therapy Clinical Science Symposium
This session reviewed a number of Abstracts.
Abstract 5509 - Sex hormone, Insulin and insulin-like growth factors in High stage endometrial cancers
Drs Huang, Bae-Jump
Dr Huang talkng now about sex hormones and insulin in endometrial cancer. GOG 210 . Understanding this is important due to increased dx of endometrial cancers. #ASCO19#gyncsmpic.twitter.com/fkSlzgKmg3
Abstract 5010 - Phase 2 trial ribociclib and letrozole in ER positive ovarian and endometrial cancers Drs Colon-Otero and Mackay
Dr Colon-Otero talking ribociclib ( cycling kinase inhibitor) and letrozole aromorase inhibitor #ASCO19#gyncsm all 3 low grade serious OC patients still on trial and progression free pic.twitter.com/sOiM0Yquo0
Dr Rustin - Maintenance - Not Ready for Prime Time
Then we had Dr Rustin’s presentation on maintenance for OC
Avastin PFS improvement but not OS , same for Parp’s ( at least to date #ASCO19#gyncsm maybe save for recurrence ? pic.twitter.com/MxoEvVedUh
6/2/2019 Gyn Cancers is it Time to Put Away the Knife?
For this session I did not have a good view of the screen so here are the high points from my notes.
Dr. Duska - Adv OC -Time to Put Away the Knife?
NACT ( Neoadjuvent chemotherapy) is a viable option for a certain population of patients with ovarian cancer
Dr Pfisterer We need a sharper smarter knife
Residual Tumor is an independent prognostic indicator. The Goal is R0 ( no visible disease left) . What prevents R0 . Factors that influence R0 are Inoperability (sugery not tolerated), Insufficiency (surgeon not capable of performing surgery . Patient survival better when surgery is done by a gyn onc.) Irresectability ( surgery not possible due to location of tumor.)
Dr Ramirez Has Laparoscopy Sung its Final Song in Cervix Cancer
Reported on LACC Study (https://www.nejm.org/doi/full/10.1056/NEJMoa1806395) Study found that radical hysterectomy by MIS (minimally invasive survery ) lead to lower rates of disease free survival compared to open hysterectomy.
Dr Boggess - There is still a Role of MIS in Cervical Cancer
6/3/2019 The More Things Change the Ovarian Cancer Edition Monk - Is It Time to Change Upfront Chemotherapy For Ovarian Cancer
